Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Next Previous
Trial Profile

An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enfortumab vedotin (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Gastrointestinal cancer; Head and neck cancer; HER2 negative breast cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms EV-202
  • Sponsors Astellas Pharma; Astellas Pharma Global Development

Most Recent Events

  • 10 Sep 2024 Status changed from recruiting to active, no longer recruiting.
  • 04 Jun 2024 Results (n=43) assessing antitumor activity in heavily pretreated non-squamous NSCLC and safety were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 04 Jun 2024 Results assessing efficacy and safety of EV in multiple tumor-specific cohorts, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top